Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (22)

2024

  1. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

    Frontiers in Neurology , Vol. 15

  2. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

    Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937

2023

  1. Hemihypomimia in Parkinson’s disease: an under-recognized clinical sign?

    Journal of Neurology

  2. Medical help-seeking intentions among patients with early Alzheimer’s disease

    Frontiers in Psychiatry, Vol. 14

  3. Recomendaciones de consenso para el tratamiento de la prevención de la migraña

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. 246-253

  4. Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

    Journal of Parkinson's disease, Vol. 13, Núm. 3, pp. 379-402

  5. [Translated article] Consensus recommendations on the preventive treatment of migraine

    Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. T246-T253

2022

  1. Awareness of Diagnosis in Persons with Early-Stage Alzheimer’s Disease: An Observational Study in Spain

    Neurology and Therapy, Vol. 11, Núm. 3, pp. 1183-1192

  2. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

  3. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

  4. Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease

    Journal of Alzheimer's disease : JAD, Vol. 90, Núm. 2, pp. 719-726

2021

  1. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

    Journal of Headache and Pain, Vol. 22, Núm. 1

  2. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

    Neurologia, Vol. 36, Núm. 8, pp. 611-617

2020

  1. Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study

    European Journal of Neurology, Vol. 27, Núm. 10, pp. 2102-2108

  2. Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine

    Neurologia, Vol. 35, Núm. 8, pp. 568-578

2019

  1. Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice

    Neurologia, Vol. 34, Núm. 6, pp. 408-417

2016

  1. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression

    BMC Neurology, Vol. 16, Núm. 1

2013

  1. MM2 subtype of sporadic Creutzfeldt-Jakob disease may underlie the clinical presentation of progressive supranuclear palsy

    Journal of Neurology, Vol. 260, Núm. 4, pp. 1031-1036

  2. Suicidal ideation in a European Huntington's disease population

    Journal of Affective Disorders, Vol. 151, Núm. 1, pp. 248-258

2009

  1. Transient neurological deficit and chronic subdural haematoma

    Revista de Neurologia